MaxCyte Reports Q3 Adjusted EBITDA of -$5.1 Million
MaxCyte reported Q3 net income of -$4.8 million. Adjusted EBITDA was -$5.1 million versus an IBES estimate of -$7.99 million.
MaxCyte reported Q3 net income of -$4.8 million. Adjusted EBITDA was -$5.1 million versus an IBES estimate of -$7.99 million.